HDAC9 and colorectal carcinoma: The anticarcinogenic action of butyrate has been linked to its inhibition of histone deacetylase (HDAC) [52], promotion of apoptosis, and anti-inflammatory properties [53], which collectively contribute to the reduction of CRC cell proliferation [54–56].